1. Research Findings


2. United States Pediatric Proton Therapy Market (Actual & Potential)
2.1 United States Pediatric Proton Therapy Market & Forecast
2.2 United States Potential Pediatric Proton Therapy Market & Forecast


3. USA Pediatric Proton Therapy Market by Age Group
3.1 By Age Group (<1) Year
3.2 By Age Group (1-4) Year
3.3 By Age Group (5-9) Year
3.4 By Age Group (10-14) Year
3.5 By Age Group (15-18) Year


4. USA Pediatric Proton Therapy Patient Number - Actual and Potential
4.1 USA Pediatric Patients Treated with Proton Therapy Actual Numbers & Forecast
4.2 United States – Pediatric Patients with Proton Therapy Potential Numbers & Forecast


5. USA Pediatric Proton Therapy Patients Numbers by Age Group
5.1 By Age (<1) Year
5.2 By Age (1- 4) Year
5.3 By Age (5- 9) Year
5.4 By Age (10-14) Year
5.5 By Age (15- 18) Year


6. Tumor Types – USA Pediatrics Proton Therapy Market (2010 – 2021)
6.1 Glioma, Low Grade – Market & Forecast
6.2 Glioma, High Grade – Market & Forecast
6.3 Medulloblastoma – Market & Forecast
6.4 Ependymoma – Market & Forecast
6.5 ATRT – Market & Forecast
6.6 Germinoma, Pure – Market & Forecast
6.7 Germ Cell Tumor – Market & Forecast
6.8 Craniopharyngioma – Market & Forecast
6.9 PNET – Market & Forecast
6.10 Pineoblastoma – Market & Forecast
6.11 Chordoma/Chondrosarcoma – Market & Forecast
6.12 Meningioma – Market & Forecast
6.13 AVM – Market & Forecast
6.14 Adenoma – Market & Forecast
6.15 Choroid Plexus Carcinoma – Market & Forecast
6.16 Retinoblastoma – Market & Forecast
6.17 Osteosarcoma – Market & Forecast
6.18 Ewing Sarcoma – Market & Forecast
6.19 Rhabdomyosarcoma – Market & Forecast
6.20 Other Sarcoma, High Grade – Market & Forecast
6.21 Other Sarcoma, Low Grade – Market & Forecast
6.22 Teratoma – Market & Forecast
6.23 Neuroblastoma – Market & Forecast
6.24 Ganglioglioma – Market & Forecast
6.25 Wilm’s Tumor – Market & Forecast
6.26 Carcinoma (non-CPC) – Market & Forecast
6.27 Lymphoma, Hodgkin’s – Market & Forecast
6.28 Lymphoma, Non-hodgkin’s – Market & Forecast
6.29 Leukemia – Market & Forecast
6.30 Desmoid – Market & Forecast
6.31 Melanoma – Market & Forecast
6.32 Pineal Parenchymal Tumor – Market & Forecast
6.33 Esthesioneuroblastoma – Market & Forecast
6.34 Angiofibroma – Market & Forecast
6.35 Extrarenal Rhabdoid Tumor – Market & Forecast
6.36 Others – Market & Forecast


7. Tumor Types – United States Pediatrics Proton Therapy Patients (2010 – 2021)
7.1 Glioma, Low Grade – Patient Numbers & Forecast
7.2 Glioma, High Grade - Patient Numbers & Forecast
7.3 Medulloblastoma - Patient Numbers & Forecast
7.4 Ependymoma - Patient Numbers & Forecast
7.5 ATRT - Patient Numbers & Forecast
7.6 Germinoma, pure - Patient Numbers & Forecast
7.7 Germ Cell Tumor - Patient Numbers & Forecast
7.8 Craniopharyngioma - Patient Numbers & Forecast
7.9 PNET - Patient Numbers & Forecast
7.10 Pineoblastoma - Patient Numbers & Forecast
7.11 Chordoma/Chondrosarcoma - Patient Numbers & Forecast
7.12 Meningioma - Patient Numbers & Forecast
7.13 AVM - Patient Numbers & Forecast
7.14 Adenoma - Patient Numbers & Forecast
7.15 Choroid Plexus Carcinoma - Patient Numbers & Forecast
7.16 Retinoblastoma - Patient Numbers & Forecast
7.17 Osteosarcoma - Patient Numbers & Forecast
7.18 Ewing Sarcoma - Patient Numbers & Forecast
7.19 Rhabdomyosarcoma - Patient Numbers & Forecast
7.20 Other Sarcoma, High Grade - Patient Numbers & Forecast
7.21 Other Sarcoma, Low Grade - Patient Numbers & Forecast
7.22 Teratoma - Patient Numbers & Forecast
7.23 Neuroblastoma - Patient Numbers & Forecast
7.24 Ganglioglioma - Patient Numbers & Forecast
7.25 Wilm’s Tumor - Patient Numbers & Forecast
7.26 Carcinoma (non-CPC) - Patient Numbers & Forecast
7.27 Lymphoma, Hodgkin’s - Patient Numbers & Forecast
7.28 Lymphoma, Non-hodgkin’s - Patient Numbers & Forecast
7.29 Leukemia - Patient Numbers & Forecast
7.30 Desmoid - Patient Numbers & Forecast
7.31 Melanoma - Patient Numbers & Forecast
7.32 Pineal Parenchymal Tumor - Patient Numbers & Forecast
7.33 Esthesioneuroblastoma - Patient Numbers & Forecast
7.34 Angiofibroma - Patient Numbers & Forecast
7.35 Extrarenal Rhabdoid Tumor - Patient Numbers & Forecast
7.36 Others - Patient Numbers & Forecast


8. Components of a Standard Proton Therapy Center
8.1 Proton Accelerator
8.1.1 Synchrotrons (example: LLUMC at Loma Linda)
8.1.2 Cyclotrons (example: MGH Boston)
8.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
8.1.4 H-minus Synchrotrons
8.1.5 Separated Sector Cyclotrons
8.1.6 Super-conducting Cyclotrons
8.1.7 Fast Cycling Synchrotron
8.2 Beam Transport System
8.3 Beam Delivery System
8.3.1 The Passive Scattering Technique
8.3.2 Beam Scanning
8.4 Nozzle
8.4.1 Single Scattering
8.4.2 Double Scattering
8.4.3 Uniform Scanning Nozzle
8.4.4 Pencil Scanning Nozzle
8.5 Treatment Planning System
8.6 Image Viewers
8.7 Patient Positioning System (PPS)
8.8 Human Resource


9. Proton Therapy – Driving Factors
9.1 Technology Advancement
9.2 Rising Prevalence of Pediatric Cancer Patients in United States


10. Proton Therapy – Challenges
10.1 Requires Huge Investment
10.2 Operations Challenges


11. Global Proton Therapy - Company Analysis (2010-2021)
11.1 IBA Proton Therapy
11.1.1 Sales Analysis
11.1.2 IBA List of Proton Therapy Centers
11.2 Varian Medical Systems
11.2.1 Sales Analysis
11.3 Mitsubishi Electric Corporation
11.3.1 Sales Analysis
11.3.2 Mitsubishi List of Proton Therapy Center
11.4 Hitachi
11.4.1 Sales Analysis
11.4.2 Hitachi List of Proton Therapy Center


12. Proton Therapy – Reimbursement Policies
12.1 Proton Therapy Reimbursement Policies for Patients
12.2 Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers